These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17086903)

  • 1. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.
    Trojano M; Russo P; Fuiani A; Paolicelli D; Di Monte E; Granieri E; Rosati G; Savettieri G; Comi G; Livrea P;
    Mult Scler; 2006 Oct; 12(5):578-85. PubMed ID: 17086903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Italian Multiple Sclerosis Database Network.
    Trojano M; Paolicelli D; Lepore V; Fuiani A; Di Monte E; Pellegrini F; Russo P; Livrea P; Comi G;
    Neurol Sci; 2006 Sep; 27 Suppl 5():S358-61. PubMed ID: 16998720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.
    Russo P; Paolillo A; Caprino L; Bastianello S; Bramanti P
    J Eval Clin Pract; 2004 Nov; 10(4):511-8. PubMed ID: 15482413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term emotional state of multiple sclerosis patients treated with interferon beta.
    Porcel J; Río J; Sánchez-Betancourt A; Arévalo MJ; Tintoré M; Téllez N; Borràs C; Nos C; Montalbán X
    Mult Scler; 2006 Dec; 12(6):802-7. PubMed ID: 17263010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
    Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
    Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
    Trojano M; Paolicelli D; Zimatore GB; De Robertis F; Fuiani A; Di Monte E; Livrea P
    Neurol Sci; 2005 Dec; 26 Suppl 4():S179-82. PubMed ID: 16388354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
    Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
    Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
    Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
    [No Abstract]   [Full Text] [Related]  

  • 20. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K; Walsh C; Antonelli G; Hutchinson M
    Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.